Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Feb 14

PMID 24523876

Citations 5

Authors

Luciane Cruz Lopes

Frederick A Spencer

Ignacio Neumann

Matthew Ventresca

Shanil Ebrahim

Qi Zhou

Neera Bhatnagar

Sam Schulman

John Eikelboom

Gordon Guyatt

Affiliations

Soon will be listed here.

Abstract

Background: Patients with atrial fibrillation considering use of anticoagulants must balance stroke reduction against bleeding risk. Knowledge of bleeding risk without the use of anticoagulants may help inform this decision.

Purpose: To determine the rate of major bleeding reported in observational studies of atrial fibrillation patients not receiving Vitamin K antagonists (VKA).

Data Sources: We searched MEDLINE, EMBASE and CINAHL to October 2011 and examined reference lists of eligible studies and related reviews.

Study Selection: All longitudinal cohort studies that included over 100 adult patients with atrial fibrillation not receiving VKA.

Data Extraction: Teams of two reviewers independently and in duplicate adjudicated eligibility, assessed risk of bias and abstracted study characteristics and outcomes.

Data Synthesis: Twenty-one eligible studies included 96,448 patients. Major bleeding rates varied widely, from 0 to 4.69 events per 100 patient-years. The pooled estimate in 13 studies with 78839 patients was 1.59 with a 99% confidence interval of 1.10 to 2.3 and median 1.42 (interquartile range 0.62-2.70). Pooled estimates for fatal bleeding and non-fatal bleeding from 4 studies that reported these outcomes were, respectively, 0.40 (0.34 to 0.46) and 1.18 (0.30 to 4.56) per 100 patient-years. In 9 randomized controlled trials (RCTs) the median rate of major bleeding in patients not receiving either anticoagulant or antiplatelet therapy was 0.6 (interquartile 0.2 to 0.90), and in 12 RCTs the median rate of major bleeding in patients receiving a single antiplatelet agent was 0.75 (interquartile 0.4 to 1.4).

Conclusion: Results suggest that patients with atrial fibrillation not receiving VKA enrolled in observational studies represent a population on average at higher risk of bleeding.

Citing Articles

Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials.

Hanlon P, Butterly E, Shah A, Hannigan L, Lewsey J, Mair F PLoS Med. 2023; 20(6):e1004176.

PMID: 37279199 PMC: 10243630. DOI: 10.1371/journal.pmed.1004176.

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis.

Chen X, Huang W, Sun A, Wang L, Mo F, Guo W Thromb J. 2021; 19(1):69.

PMID: 34600549 PMC: 8487538. DOI: 10.1186/s12959-021-00322-6.

Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort.

Ehrlinder H, Orsini N, Modig K, Hofman-Bang C, Wallen H, Gigante B Int J Cardiol Heart Vasc. 2020; 27:100505.

PMID: 32258363 PMC: 7114891. DOI: 10.1016/j.ijcha.2020.100505.

Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.

Huang W, Singer D, Wu Y, Chiang C, Weng H, Lee M JAMA Neurol. 2018; 75(12):1511-1518.

PMID: 30105396 PMC: 6583193. DOI: 10.1001/jamaneurol.2018.2215.

Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project.

Guo Y, Zhang Y, Shi X, Shan Z, Wang C, Wang Y Sci Rep. 2016; 6:31755.

PMID: 27557876 PMC: 4997334. DOI: 10.1038/srep31755.

References

Lopes L, Spencer F, Neumann I, Ventresca M, Ebrahim S, Zhou Q . Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. Clin Pharmacol Ther. 2013; 94(3):367-75. DOI: 10.1038/clpt.2013.99. View

Singer D, Chang Y, Fang M, Borowsky L, Pomernacki N, Udaltsova N . The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151(5):297-305. PMC: 2777526. DOI: 10.7326/0003-4819-151-5-200909010-00003. View

Gage B, Yan Y, E Milligan P, Waterman A, Culverhouse R, Rich M . Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3):713-9. DOI: 10.1016/j.ahj.2005.04.017. View

. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994; 343(8899):687-91. View

Lai H, Aronow W, Kalen P, Adapa S, Patel K, Goel A . Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2011; 2:33-7. PMC: 3108764. DOI: 10.2147/ijnrd.s7781. View

Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M . Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997; 28(5):1015-21. DOI: 10.1161/01.str.28.5.1015. View

Meiltz A, Zimmermann M, Urban P, Bloch A . Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace. 2008; 10(6):674-80. DOI: 10.1093/europace/eun086. View

. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84(2):527-39. DOI: 10.1161/01.cir.84.2.527. View

You J, Singer D, Howard P, Lane D, Eckman M, Fang M . Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e531S-e575S. PMC: 3278056. DOI: 10.1378/chest.11-2304. View

10.

Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K . Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med. 2003; 254(1):95-101. DOI: 10.1046/j.1365-2796.2003.01159.x. View

11.

Mant J, Hobbs F, Fletcher K, Roalfe A, Fitzmaurice D, Lip G . Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586):493-503. DOI: 10.1016/S0140-6736(07)61233-1. View

12.

Parkash R, Wee V, Gardner M, Cox J, Thompson K, Brownell B . The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol. 2007; 23(6):457-61. PMC: 2650665. DOI: 10.1016/s0828-282x(07)70784-5. View

13.

Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y . Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2005; 37(2):447-51. DOI: 10.1161/01.STR.0000198839.61112.ee. View

14.

Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B . Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1(8631):175-9. DOI: 10.1016/s0140-6736(89)91200-2. View

15.

Lee B, Park J, Park J, Park J, Kwak J, Hwang E . The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. J Cardiovasc Electrophysiol. 2009; 21(5):501-7. DOI: 10.1111/j.1540-8167.2009.01661.x. View

16.

Darkow T, Vanderplas A, Lew K, Kim J, Hauch O . Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin. 2005; 21(10):1583-94. DOI: 10.1185/030079905X61956. View

17.

Hansen M, Sorensen R, Clausen M, Fog-Petersen M, Raunso J, Gadsboll N . Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170(16):1433-41. DOI: 10.1001/archinternmed.2010.271. View

18.

Shen A, Yao J, Brar S, Jorgensen M, Chen W . Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50(4):309-15. DOI: 10.1016/j.jacc.2007.01.098. View

19.

. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998; 279(16):1273-7. View

20.

Boccuzzi S, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J . Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Curr Med Res Opin. 2009; 25(12):2853-64. DOI: 10.1185/03007990903196422. View